Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Purple Biotech (PPBT) Consolidated Net Income (2016 - 2025)

Purple Biotech has reported Consolidated Net Income over the past 6 years, most recently at -$8.1 million for Q4 2022.

  • Quarterly Consolidated Net Income fell 2375.99% to -$8.1 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $7.4 million through Dec 2022, up 1059.5% year-over-year, with the annual reading at $26.9 million for FY2025, 136.17% up from the prior year.
  • Consolidated Net Income was -$8.1 million for Q4 2022 at Purple Biotech, down from $4.8 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $7.2 million in Q1 2022 and troughed at -$8.1 million in Q4 2022.
  • The 5-year median for Consolidated Net Income is $354000.0 (2021), against an average of $1.3 million.
  • The largest YoY upside for Consolidated Net Income was 172600.0% in 2022 against a maximum downside of 2375.99% in 2022.
  • A 5-year view of Consolidated Net Income shows it stood at $3.2 million in 2018, then rose by 7.87% to $3.4 million in 2019, then crashed by 98.9% to $38000.0 in 2020, then skyrocketed by 831.58% to $354000.0 in 2021, then plummeted by 2375.99% to -$8.1 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Consolidated Net Income are -$8.1 million (Q4 2022), $4.8 million (Q3 2022), and $3.4 million (Q2 2022).